Mirvaso (Brimonidine Tartrate)

Brimonidine tartrate, the active ingredient in Mirvaso, is a Alpha-2 adrenergic agonist presented as a 0.33% (w/w) gel for topical use. It treats persistent facial erythema associated with rosacea in adults. The formulation is designed for once‑daily application to the affected facial areas, providing a localized vasoconstrictive effect that reduces visible redness.

GNH USA supplies Mirvaso as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory support for cross‑border distribution global.

Mirvaso (brimonidine tartrate) is indicated for the management of persistent facial erythema in rosacea, a chronic inflammatory skin condition.

- Persistent facial erythema associated with rosacea: Reduces visible redness and improves facial appearance. - Transient facial flushing in rosacea: Decreases frequency and intensity of flushing episodes. - Overall rosacea‑related redness: Provides adjunctive control of cutaneous vasodilation.

Adverse reactions reported with Mirvaso are generally mild to moderate and reflect local skin tolerance.

Common Side Effects: - Application site irritation: mild redness, burning or stinging at the site of application. - Dryness: sensation of skin dryness or flaking. - Pruritus: itching of the treated area.

Serious or Rare Side Effects: - Allergic contact dermatitis: rash, swelling, or severe itching requiring medical attention. - Hypotension: systemic absorption leading to low blood pressure, rarely observed. - Cardiovascular events: chest pain or palpitations in susceptible individuals.

Before using Mirvaso, consider the following precautions.

- Pregnancy: safety not established; avoid use unless benefits outweigh risks. - Breastfeeding: unknown excretion; discuss with healthcare provider. - Concurrent rosacea therapies: assess for additive irritation when combined with other topical agents. - Skin integrity: do not apply to broken, infected, or inflamed skin. - Allergy history: avoid if known hypersensitivity to brimonidine or formulation components. - Store at room temperature: keep in original tube, protect from light and moisture.

Mirvaso may interact with other agents that affect vascular tone or systemic adrenergic activity.

Major Interactions (Avoid): - Systemic alpha‑2 agonists (e.g., clonidine): additive vasoconstrictive effect may increase blood pressure changes. - Non‑selective beta‑blockers: potential for enhanced hypotensive response.

Moderate Interactions (Monitor Closely): - Topical irritants (e.g., retinoids, benzoyl peroxide): may increase local skin irritation. - Other vasoconstrictive agents (e.g., phenylephrine nasal sprays): monitor for excessive vasoconstriction.